References

Basketter DA, Marriott M, Gilmour NJ, White IR. Strong irritants masquerading as skin allergens: the case of benzalkonium chloride. Contact dermatitis. 2004; 50:(4)213-217 https://doi.org/10.1111/j.0105-1873.2004.00331.x

Baxter Corporation. Gentamicin. 2013. https://web.archive.org/web/20160304124731/ (accessed November 18 2019)

Ototoxicity caused by aminoglycosides. 2007. 10.1136/bmj.39301.680266.ae (accessed 18 November 2019)

Drehobl M, Guerrero JL, Lacarte PR, Goldstein G, Mata FS, Luber S. Comparison of efficacy and safety of ciprofloxacin otic solution 0.2% versus polymyxin B-neomycin-hydrocortisone in the treatment of acute diffuse otitis externa. Current Medical Research and Opinion. 2008; 24:(12)3531-3542 https://doi.org/10.1185/03007990802583845

Electronic Medicines Compendium. Genticin (Gentamicin 0.3% w/v) Eye/Ear Drops - Summary of Product Characteristics (SmPC) - (emc). 2019. https://www.medicines.org.uk/emc/product/6552/smpc#PHARMACOLOGICAL_PROPS (accessed 18 November 2019)

Electronic Medicines Compendium. Otosporin Ear Drops 10ml - Summary of Product Characteristics (SmPC) - (emc). 2017a. https://www.medicines.org.uk/emc/product/2474/smpc (accessed 18 November, 2019)

Electronic Medicines Compendium. CILODEX 3 mg/ml/1 mg/ml ear drops, suspension - Summary of Product Characteristics (SmPC) - (emc). 2017b. https://www.medicines.org.uk/emc/product/7137/smpc (accessed 26 November 2019)

Anwar K, Gohar MS, Gohar MS. Otomycosis; clinical features, predisposing factors and treatment implications. Pakistan Journal of Medical Sciences. 1969; 30:(3) https://doi.org/10.12669/pjms.303.4106

Hui CP. Acute otitis externa. Paediatrics & Child Health. 2013; 18:(2)96-98 https://doi.org/10.1093/pch/18.2.96

Huth ME, Ricci AJ, Cheng AG. Mechanisms of Aminoglycoside Ototoxicity and Targets of Hair Cell Protection. International Journal of Otolaryngology. 2011; 2011:1-19 https://doi.org/10.1155/2011/937861

Jones RN, Milazzo J, Seidlin M. Ofloxacin Otic Solution for Treatment of Otitis Externa in Children and Adults. Archives of Otolaryngology - Head and Neck Surgery. 1997; 123:(11)1193-1200 https://doi.org/10.1001/archotol.1997.01900110047007

Kaushik V, Malik T, Saeed SR. Cochrane review: Interventions for acute otitis externa. Evidence-Based Child Health: A Cochrane Review Journal. 2011; 6:(2)444-560 https://doi.org/10.1002/ebch.711

Leis JA, Rutka JA, Gold WL. Aminoglycoside-induced ototoxicity. Canadian Medical Association Journal. 2014; 187:(1)E52-E52 https://doi.org/10.1503/cmaj.140339

Lorente J, Sabater F, Rivas MP, Fuste J, Risco J, Gómez M. Ciprofloxacin plus fluocinolone acetonide versus ciprofloxacin alone in the treatment of diffuse otitis externa. The Journal of laryngology and otology. 2014; 128:(7)591-598 https://doi.org/10.1017/S0022215114001157

National Institute on Deafness and Other Communication Disorders. Ear Infections in Children. 2015. http://www.nidcd.nih.gov/health/ear-infections-children (accessed 18 November 2019)

NCBI. Fluoroquinolones. 2014. https://www.ncbi.nlm.nih.gov/books/NBK547840/ (accessed November 18 2019)

NHS Choices. Side effects - Antibiotics. 2019. https://www.nhs.uk/conditions/antibiotics/side-effects/ (accessed 18 November 2019)

NICE. BNF is only available in the UK. 2009. https://bnf.nice.org.uk/drug/ (accessed 18 November 2019)

Ninkovic G, Dullo V, Saunders NC. Microbiology of otitis externa in the secondary care in United Kingdom and antimicrobial sensitivity. Auris Nasus Larynx. 2008; 35:(4)480-484 https://doi.org/10.1016/j.anl.2007.09.013

Rosenfeld RM, Schwartz SR, Cannon CR Clinical Practice Guideline. Otolaryngology–Head and Neck Surgery. 2014; 150:S1-S24 https://doi.org/10.1177/0194599813517083

Singh T. Swimmer's ear-symptoms, causes, and treatment. Annals of Tropical Medicine and Public Health. 2017; 10:(4) https://doi.org/10.4103/atmph.atmph_123_17

Wang X, Winterstein A, Alrwisan A, Antonelli P. Risk for Tympanic Membrane Perforation After Quinolone Ear Drops for Acute Otitis Externa. Clinical Infectious Diseases. 2019; https://doi.org/10.1093/cid/ciz345

Effective pharmaceutical management of Acute Otitis Externa: guidance and prescribing considerations

02 December 2019
Volume 1 · Issue 12

Abstract

Acute Otitis Externa is a common condition observed by physicians, particularly in primary care. The condition usually occurs due to bacterial infection, so antibiotic therapy is frequently indicated. Oral antibiotics are rarely necessary but are still being prescribed, despite a wide range of available topical preparations. Choosing a topical preparation can sometimes be challenging for prescribers, however, consideration of a range of different factors is necessary. This article provides a review of the currently recommended prescribing practice and outlines key topical antibiotic ear preparations available in the UK for treatment of Acute Otitis Externa. As no one topical ear preparation is more effective than another, a consideration of the benefits and risks of each treatment is needed to enable therapeutic resolution of Acute Otitis Externa. Furthermore, patient compliance should be adequately considered to increase the likelihood of patient adherence to treatment.

Acute otitis externa (AOE), also known as swimmer's ear, is defined by widespread inflammation of the external auditory canal and is considered acute if it lasts three weeks or less (National Institute for Health and Care Excellence (NICE), 2018). The symptoms of AOE range from mild to severe and include ottorhoea, erythema, pain and oedema. One third of patients may also suffer from some form of hearing loss (Hui et al, 2013).

The condition usually occurs due to bacterial infection, and the microbiology surrounding AOE is widely established. The principle pathogens of the condition are Pseudomonas aeruginosa and Staphylococcus aureus, and the infection often occurs in a polymicrobial setting (NICE, 2018). Fungal involvement is uncommon in primary AOE, but is more common in cases of chronic otitis externa or when AOE has previously been treated with topical antibiotics (Rosenfield et al, 2014).

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month